RxDoctor Payments DataLook up a doctor →

Andrew Seevaratnam, MD

Critical Care Medicine · Ocala, FLNPI 1891971271

Payments from drug & device makers

$45,922in general payments, 2019–2025

Across 499 payments — averaging $92.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$33K
  • Pinnacle Biologics, Inc$2K
  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$889
  • Intuitive Surgical$720
  • plus $5K from 42 others

What the payments were for

  • Speaking & faculty fees$31,00068%
  • Travel & lodging$3,9008%
  • Food & beverage$10,77423%
  • Education$1460%
  • Gifts$1010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,922 in reported general payments places this provider in the 90th percentile of 618 critical care medicine providers in Florida.

See all critical care medicine providers in Florida

Medicare billing

Part B allowed, 2024
$365,886
Medicare patients
1,191
Services billed
2,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate22$373,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter335$303,512
Dupixent PenDupilumab17$74,758
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr129$74,364
Breztri AerosphereBudesonide/Glycopyr/Formoterol68$52,933
Breo ElliptaFluticasone/Vilanterol69$40,592
Spiriva RespimatTiotropium Bromide59$39,423
Stiolto RespimatTiotropium Br/Olodaterol Hcl49$32,865
SymbicortBudesonide/Formoterol Fumarate44$17,218
Albuterol Sulfate HfaAlbuterol Sulfate255$8,689
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,893
Advair HfaFluticasone Propion/Salmeterol12$5,132
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,260
Wixela InhubFluticasone Propion/Salmeterol33$4,209
BreynaBudesonide/Formoterol Fumarate15$3,890

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$889$445,659130 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$33,490$418,468533 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$1,405$76,045124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 618 critical care medicine providers in Florida.

Other critical care medicine in Ocala

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →